MedTrace Logo

A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers

NCT04377646 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 660

Last updated 2020-05-06

No results posted yet for this study

Summary

A multicenter randomized clinical trial aiming to assess the efficacy of hydroxychloroquine associated to Zinc compared to hydroxychloroquine, in the prevention of Military Health Professionals Exposed to SARS CoV2 in Tunisia

Conditions

  • Sars-CoV2
  • COVID19

Interventions

DRUG

Hydroxychloroquine

400 mg at day 1 and day 2, then 400 mg weekly up to 2 months

DRUG

Hydroxychloroquine (placebo)

1 pill at day 1 and day 2, then 1 pill weekly up to 2 months

DRUG

Zinc

15 mg per day up to 2 months

DRUG

Zinc (Placebo)

1 pill per day up to 2 months

Sponsors & Collaborators

  • UR17DN02 : Autoimmune Diseases Research Unit

    collaborator UNKNOWN

  • Dacima Consulting

    collaborator OTHER

  • Military Hospital of Tunis

    lead OTHER

Principal Investigators

  • Faida Ajili, MD · Military Hospital of Tunis

  • Nejla Mrabet, PhD · Military Hospital of Tunis

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-05-04
Primary Completion
2020-05-24
Completion
2020-07-31

Countries

  • Tunisia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04377646 on ClinicalTrials.gov